ASTRAZENECA PLC Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-03-05: Form 6-K; Period of report 2019-03-05; Description ANNUAL FINANCIAL REPORT; Document a8884r.htm.
- 2019-03-01: Form 6-K; Period of report 2019-03-01; Description TOTAL VOTING RIGHTS; Document a6326r.htm.
- 2019-03-01: Form 6-K; Period of report 2019-03-01; Description LYNPARZA RECEIVES POSITIVE EU CHMP OPINION; Document a6341r.htm.
- 2019-02-26: Form 6-K; Period of report 2019-02-26; Description LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION; Document a1149r.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2019-03-05 | 6-K | 2019-03-05 | ANNUAL FINANCIAL REPORT | a8884r.htm |
| 2019-03-01 | 6-K | 2019-03-01 | TOTAL VOTING RIGHTS | a6326r.htm |
| 2019-03-01 | 6-K | 2019-03-01 | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION | a6341r.htm |
| 2019-02-26 | 6-K | 2019-02-26 | LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION | a1149r.htm |
| 2019-02-25 | 6-K | 2019-02-25 | BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT | a9752q.htm |
| 2019-02-14 | 6-K | 2019-02-14 | ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS | a9540p.htm |
| 2019-02-06 | 6-K | 2019-02-06 | US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION | a1782p.htm |
| 2019-02-05 | 6-K | 2019-02-05 | US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION | a0843p.htm |
| 2019-02-05 | 6-K | 2019-02-05 | EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 | a0838p.htm |
| 2019-02-01 | 6-K | 2019-02-01 | TOTAL VOTING RIGHTS | a8647o.htm |
| 2019-02-01 | 6-K | 2019-02-01 | FORXIGA RECEIVES POSITIVE EU CHMP OPINION | a8718o.htm |
| 2019-01-25 | 6-K | 2019-01-25 | COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS | a1720o.htm |
| 2019-01-07 | 6-K | 2019-01-07 | ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES | a4022m.htm |
| 2019-01-02 | 6-K | 2019-01-02 | TOTAL VOTING RIGHTS | a9936l.htm |